TrialJournal of clinical oncology : official journal of the American Society of Clinical Oncology2025

Metronomic Capecitabine Plus Aromatase Inhibitor as Initial Therapy in Patients With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: The Phase III MECCA Trial.

Ruo-Xi Hong et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.